B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 american thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)

Article  PubMed  PubMed Central  Google Scholar 

M. Schlumberger, E. Baudin, Serum thyroglobulin determination in the follow-up of patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 138, 249–252 (1998)

Article  PubMed  CAS  Google Scholar 

L. Giovanella, Highly sensitive thyroglobulin measurements in differentiated thyroid carcinoma management. Clin. Chem. Lab. Med. 46, 1067–1073 (2008)

Article  PubMed  CAS  Google Scholar 

B.R. Haugen, F. Pacini, C. Reiners, M. schlumberger, P.W. Ladenson, S.I. Sherman et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J. Clin. Endocrinol. Metab. 84, 3877–3885 (1999)

PubMed  CAS  Google Scholar 

C.A. Spencer, M. Takeuchi, M. Kazarosyan, C.C. Wang, R.B. Guttler, P.A. Singer et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J. Clin. Endocrinol. Metab. 83, 1121–1127 (1998)

PubMed  CAS  Google Scholar 

J.K. Chung, Y.J. Park, T.Y. Kim, Y. So, S.K. Kim, D.J. Park et al. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin. Endocrinol. 57, 215–221 (2002)

Article  Google Scholar 

C.A. Spencer, J.S. Lopresti, Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat. Clin. Pract. Endocrinol. Metab. 4, 223–233 (2008)

Article  PubMed  CAS  Google Scholar 

K. Jo, D.J. Lim, Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer. Korean J. Intern. Med. 33(6 Nov), 1050–1057 (2018). https://doi.org/10.3904/kjim.2018.289

Article  PubMed  PubMed Central  CAS  Google Scholar 

F. Pacini, S. Mariotti, N. Formica, R. Elisei, S. Anelli, E. Capotorti et al. Thyroid autoantibodies in thyroid cancer: incidence and relationship with tumour outcome. Acta Endocrinol. 119, 373–380 (1988)

CAS  Google Scholar 

D. Rubello, M.E. Girelli, D. Casara, M. Piccolo, A. Perin, B. Busnardo, Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer. J. Endocrinol. Investig. 13, 737–742 (1990)

Article  CAS  Google Scholar 

L. Chiovato, F. Latrofa, L.E. Braverman, F. Pacini, M. Capezzone, L. Masserini et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 139, 346–351 (2003)

Article  PubMed  CAS  Google Scholar 

A. Piccardo, P. Trimboli, L. Foppiani, G. Treglia, G. Ferrarazzo, M. Massollo et al. PET/CT in thyroid nodule and differentiated thyroid cancer patients. The evidence-based state of the art. Rev. Endocr. Metab. Disord. 20(1 Mar), 47–64 (2019)

Article  PubMed  Google Scholar 

F. Bertagna, D. Albano, G. Bosio, A. Piccardo, B. Dib, R. Giubbini, 18F-FDG-PET/CT in patients affected by differentiated thyroid carcinoma with positive thyroglobulin level and negative 131I whole body scan. It’s value confirmed by a bicentric experience. Curr. Radiopharm. 9(3), 228–234 (2016)

Article  PubMed  CAS  Google Scholar 

D. Albano, M. Tulchinsky, F. Dondi, A. Mazzoletti, D. Lombardi, F. Bertagna et al. Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET/CT in non-iodine avid differentiated thyroid carcinoma. Eur. J. Nucl. Med. Mol. Imaging 48, 461–468 (2021)

Article  PubMed  CAS  Google Scholar 

Y. Liu, The role of 18F-FDG PET/CT in the follow-up of well-differentiated thyroid cancer with negative thyroglobulin but positive and/or elevated antithyroglobulin antibody. Nucl. Med. Commun. 37, 577–582 (2016)

Article  PubMed  CAS  Google Scholar 

C. Nanni, D. Rubello, S. Fanti, M. Farsad, V. Ambrosini, L. Rampin et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed. Pharmacother. 60, 409–413 (2006)

Article  PubMed  CAS  Google Scholar 

S.J. Kim, S.W. Lee, K. Pak, S.R. Shim, Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab. Endocr. Relat. Cancer 25, 643–652 (2018)

Article  PubMed  CAS  Google Scholar 

J.I. Bang, S. Park, K. Kim, Y. Seo, A. Chong, C.M. Hong et al. The diagnostic value of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin/thyroglobulin antibody levels and negative iodine scintigraphy: a systematic review and meta-analysis. Thyroid 33, 1224–1236 (2023)

Article  PubMed  CAS  Google Scholar 

M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 29, 372 (2021)

Google Scholar 

P.F. Whiting, A.W. Rutjes, M.E. Westwood, S. Mallett, J.J. Deeks, J.B. Reitsma et al. QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155, 529–536 (2011)

Article  PubMed  Google Scholar 

R. Sadeghi, G. Treglia, Systematic reviews and meta-analyses of diagnostic studies: a practical guideline. Clin. Transl. Imaging 5, 83–87 (2017)

Article  Google Scholar 

J.H. Seo, S.W. Lee, B.C. Ahn, J. Lee, Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin. Endocrinol. 72, 558–563 (2010)

Article  CAS  Google Scholar 

T.V. Bogsrud, I.D. Hay, D. Karantanis, M.A. Nathan, B.P. Mullan, G.A. Wiseman et al. Prognostic value of 18F-fluorodeoxyglucose-positron emission tomography in patients with differentiated thyroid carcinoma and circulating antithyroglobulin autoantibodies. Nucl. Med. Commun. 32, 245–251 (2011)

Article  PubMed  Google Scholar 

K. Kingpetch, R. Pipatrattana, S. Tepmongkol, S. Sirisalipoch, T. Chaiwatanarat, Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody. J. Med. Assoc. Thai. 94, 1238–1244 (2011)

PubMed  Google Scholar 

S. Viedma, I. Borrego Dorado, J.R. Rodríguez Rodríguez, E. Navarro González, R. Vázquez Albertino, R. Fernández López et al. Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan. Revista Española de Medicina Nuclear e Imagen Mol. 30, 77–82 (2011)

Google Scholar 

E. Ozkan, C. Soydal, M. Araz, G. Aras, E. Ibis, The additive clinical value of 18F-FDG PET/CT in defining the recurrence of disease in patients with differentiated thyroid cancer who have isolated increased antithyroglobulin antibody levels. Clin. Nucl. Med. 37, 755–758 (2012)

Article  PubMed  Google Scholar 

E. Ozkan, G. Aras, N.O. Kucuk, Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin. Nucl. Med. 38, 326–331 (2013)

Article  PubMed  Google Scholar 

S. Asa, S.Y. Aksoy, B. Vatankulu, A. Aliyev, L. Uslu, M. Ozhan et al. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. Ann. Nucl. Med. 28, 970–979 (2014)

Article  PubMed  CAS  Google Scholar 

S.J. Choi, K.P. Jung, S.S. Lee, Y.S. Park, S.M. Lee, S.K. Bae, Clinical usefulness of F-18 FDG PET/CT in papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody. Nucl. Med. Mol. Imaging 50, 130–136 (2016)

Article  PubMed  CAS  Google Scholar 

Z.L. Qiu, W.J. Wei, C.T. Shen, H.J. Song, X.Y. Zhang, Z.K. Sun et al. Diagnostic performance of 18F-FDG PET/CT in papillary thyroid carcinoma with negative 131I-WBS at first postablation, negative Tg and progressively increased TgAb level. Sci. Rep. 7, 2849 (2017)

Article  PubMed  PubMed Central  Google Scholar 

S. Morbelli, G. Ferrarazzo, E. Pomposelli, F. Pupo, G. Pesce, I. Calamia et al. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications. J. Endocrinol. Investig. 40, 417–424 (2017)

Article  CAS  Google Scholar 

J. Liu, B. Liu, Y. Yu, F. Chao, Y. Liu, Han X.18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan. Hell J. Nucl. Med. 21, 24–27 (2018)

PubMed